Accumulation of Lysosphingolipids in Tissues from Patients with GM1 and GM2 Gangliosidoses

Abstract: By using a sensitive method, we assayed lysocom‐pounds of gangliosides and asialogangliosides in tissues from four patients with GM2 gangliosidosis (one with Sand‐hoff disease and three with Tay‐Sachs disease) and from three patients with GM1 gangliosidosis [one with infantile type (fetus), one with late‐infantile, and one with adult type]. In the brain and spinal cord of all the patients except for an adult GM 1 gangliosidosis patient, abnormal accumulation of the lipids was observed, though the concentration in the fetal tissue was low. In GM2 gangliosidosis, the amounts of lyso GM2 ganglioside accumulated in the brain were similar among the patient with Sandhoff disease and the patients with Tay‐Sachs disease, whereas the concentration of asialo lyso GM2 ganglioside in the brain was higher in the former patient than in the latter patients. By comparing the sphingoid bases of neutral sphingolipids, gangliosides, and lysosphingolipids, it was suggested that lysosphingolipids in the diseased tissue are synthesized by sequential glycosylation from free sphingoid bases, but not by deacyla‐tion of the sphingolipids. Because lysosphingolipids are known to be cytotoxic, the abnormally accumulated lysosphingolipids may well be the pathogenetic agent for the neuronal degeneration in gangliosidoses.

[1]  T. Kobayashi,et al.  A sensitive assay of lysogangliosides using high-performance liquid chromatography. , 1991, Biochimica et biophysica acta.

[2]  M. Taniike,et al.  Study of pathogenesis in twitcher mouse, an enzymatically authentic model of Krabbe's disease , 1990, Journal of the Neurological Sciences.

[3]  Y. Eto,et al.  Lysosulfatide (Sulfogalactosylsphingosine) Accumulation in Tissues from Patients with Metachromatic Leukodystrophy , 1990, Journal of neurochemistry.

[4]  Y. Igarashi,et al.  A specific enhancing effect of N,N-dimethylsphingosine on epidermal growth factor receptor autophosphorylation. Demonstration of its endogenous occurrence (and the virtual absence of unsubstituted sphingosine) in human epidermoid carcinoma A431 cells. , 1990, The Journal of biological chemistry.

[5]  S. Hakomori,et al.  Enzymatic synthesis of N,N-dimethyl-sphingosine: demonstration of the sphingosine: N-methyltransferase in mouse brain. , 1989, Biochemical and biophysical research communications.

[6]  S. Hakomori,et al.  Effect of chemically well-defined sphingosine and its N-methyl derivatives on protein kinase C and src kinase activities. , 1989, Biochemistry.

[7]  Takurou Kobayashi,et al.  Infantile and fetal globoid cell leukodystrophy: Analysis of galactosylceramide and galactosylsphingosine , 1988, Annals of neurology.

[8]  S. Hakomori,et al.  Synthesis and characterization of lyso-GM3 (II3Neu5Ac Lactosyl sphingosine), de-N-acetyl-GM3 (II3NeuNH2 lactosyl Cer), and related compounds. , 1988, Carbohydrate research.

[9]  Takurou Kobayashi,et al.  Free sphingoid bases in normal murine tissues. , 1988, European journal of biochemistry.

[10]  J. Månsson,et al.  Composition of Gangliosides and Neutral Glycosphingolipids of Brain in Classical Tay‐Sachs and Sandhoff Disease: More Lyso‐GM2 in Sandhoff Disease? , 1987, Journal of neurochemistry.

[11]  Takurou Kobayashi,et al.  Accumulation of Galactosylsphingosine (Psychosine) in the Twitcher Mouse: Determination by HPLC , 1987, Journal of neurochemistry.

[12]  Y. Hannun,et al.  Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. , 1987, Science.

[13]  Kobayashi Takuro,et al.  Incorporation and degradation of GM1 ganglioside and asialoGm1 ganglioside in cultured fibroblasts from normal individuals and patients with β-galactosidase deficiency , 1986 .

[14]  H. Egge,et al.  Synthesis of lysogangliosides. , 1985, Biochemistry.

[15]  H. Igisu,et al.  Progressive accumulation of toxic metabolite in a genetic leukodystrophy. , 1984, Science.

[16]  J. Evans,et al.  Acetonitrile-hydrochloric acid hydrolysis of gangliosides for high performance liquid chromatographic analysis of their long chain bases. , 1983, Journal of lipid research.

[17]  R. Yu,et al.  Analysis of brain lipids by high performance thin-layer chromatography and densitometry. , 1983, Journal of lipid research.

[18]  L. Svennerholm,et al.  Accumulation of Glucosylceramide and Glucosylsphingosine (Psychosine) in Cerebrum and Cerebellum in Infantile and Juvenile Gaucher Disease , 1982, Journal of neurochemistry.

[19]  Takurou Kobayashi,et al.  Chronic GM1 gangliosidosis presenting as dystonia: II. Biochemical studies , 1981, Annals of neurology.

[20]  R. Yu,et al.  High-performance thin-layer chromatography and densitometric determination of brain ganglioside compositions of several species. , 1978, Analytical biochemistry.

[21]  K. Sugano Susceptibility of ganglioside GM1 to a new bacterial neuraminidase , 1978, FEBS letters.

[22]  T. Taketomi,et al.  PHYSIOLOGICAL ACTIVITY OF PSYCHOSINE. , 1964, The Japanese journal of experimental medicine.

[23]  A. George The metabolic basis of inherited disease , 1961 .

[24]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[25]  J. Callahan,et al.  Psychosine and Sphingosylphosphorylcholine Bind to Mitochondrial Membranes and Disrupt their Function , 1988 .

[26]  H. Egge,et al.  Occurrence of lysoganglioside lyso-GM2 (II3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain. , 1986, Biological chemistry Hoppe-Seyler.

[27]  K. Sandhoff,et al.  Purification and characterization of an activator protein for the degradation of glycolipids GM2 and GA2 by hexosaminidase A. , 1979, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.